AP-SA02
- Generic Name
- AP-SA02
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects with S. Aureus Bacteremia
Phase 1
Completed
- Conditions
- BacteremiaBacteremia StaphStaphylococcus AureusBacteremia Due to Staphylococcus AureusStaphylococcus Aureus Bacteremia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Armata Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05184764
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸University of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath